Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR)

✍ Scribed by Gheath Alatrash; Maher Albitar; Susan O’Brien; Xuemei Wang; Taghi Manshouri; Stefan Faderl; Alessandra Ferrajoli; Jan Burger; Guillermo Garcia-Manero; Hagop M. Kantarjian; Susan Lerner; Michael J. Keating; William G. Wierda

• Book ID: 108676566
• Publisher: John Wiley and Sons
• Year: 2010
• Tongue: English
• Weight: 143 KB
• Volume: 148
• Category: Article
• ISSN: 0007-1048
• DOI: 10.1111/j.1365-2141.2009.07965.x